List of Excipients in Branded Drug VERMOX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Pharmaceuticals Inc	VERMOX	mebendazole	50458-675	CELLULOSE, MICROCRYSTALLINE
Janssen Pharmaceuticals Inc	VERMOX	mebendazole	50458-675	CROSPOVIDONE
Janssen Pharmaceuticals Inc	VERMOX	mebendazole	50458-675	MAGNESIUM STEARATE
Janssen Pharmaceuticals Inc	VERMOX	mebendazole	50458-675	POVIDONE
Janssen Pharmaceuticals Inc	VERMOX	mebendazole	50458-675	STRAWBERRY

Vermox Excipient Strategy and Commercial Opportunities for Mebendazole Products

Last updated: August 1, 2026

Vermox is a mebendazole anthelmintic product with a low-cost active ingredient, mature clinical profile, and limited compound-patent protection. Commercial differentiation is therefore concentrated in excipient selection, dosage-form performance, palatability, pediatric usability, supply reliability, and regulatory execution. The strongest opportunities are taste-masked chewables, dispersible tablets, oral suspensions, and excipient systems that improve dose uniformity without materially increasing manufacturing cost.

What is Vermox and which drug substance does it contain?

Vermox contains mebendazole, a benzimidazole anthelmintic used against intestinal nematodes, including pinworm, whipworm, roundworm, and hookworm infections. Depending on the market, Vermox is supplied primarily as 100 mg tablets or chewable tablets. Product composition, indications, dosing instructions, and excipient declarations vary by jurisdiction.

Product attribute	Commercial relevance
Active ingredient	Mebendazole
Typical strength	100 mg
Main therapeutic category	Anthelmintic
Common dosage forms	Conventional tablet, chewable tablet, oral suspension in selected markets
Principal users	Adults, children, public-health programs, travelers, primary-care patients
Prescription status	Varies by country
Compound patent position	Mature and generally outside meaningful basic-compound exclusivity
Main differentiation levers	Palatability, dose flexibility, administration convenience, stability, packaging, cost

The low dose and poor aqueous solubility of mebendazole make excipient selection important. The formulation must provide adequate content uniformity, acceptable dissolution, physical stability, and reliable administration despite the drug’s limited water solubility.

What excipients are used in Vermox and comparable mebendazole products?

Public product information identifies conventional tablet and chewable-tablet excipients such as starches, cellulose derivatives, lactose, povidone, magnesium stearate, talc, silicon dioxide, sweeteners, and flavoring systems. Exact compositions differ by manufacturer and country.

Typical excipient functions

Excipient category	Examples used in mebendazole products	Primary function
Diluent	Lactose monohydrate, microcrystalline cellulose, maize starch	Provides tablet mass and improves compression
Disintegrant	Maize starch, sodium starch glycolate, crospovidone	Promotes tablet breakup
Binder	Povidone, pregelatinized starch	Improves granule and tablet strength
Lubricant	Magnesium stearate, hydrogenated vegetable oil	Reduces tooling friction
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Sweetener	Sodium saccharin, sucralose, sugar alcohols	Reduces bitterness
Flavor	Fruit or vanilla flavors	Improves pediatric acceptability
Surfactant	Sodium lauryl sulfate or other wetting agents	Supports wetting and dissolution
Suspending agent	Cellulose polymers, xanthan gum, carbomers	Maintains suspension uniformity
Preservative	Product-dependent	Controls microbial growth in aqueous products
Coloring agent	Product-dependent	Supports identification and patient acceptability

A U.S. mebendazole chewable-tablet label lists excipients including colloidal silicon dioxide, corn starch, hydrogenated vegetable oil, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, sodium lauryl sulfate, sodium saccharin, and talc.[1] Those ingredients illustrate a conventional strategy combining compression performance, wetting, disintegration, and taste support.

The presence of an excipient in a reference product does not create a requirement to use the same material in a generic or line extension. A developer can use a different excipient system if the product meets applicable quality, safety, bioequivalence, dissolution, and stability requirements.

Which excipient properties matter most for Vermox formulation?

The highest-value properties are wetting performance, taste masking, compressibility, low moisture sensitivity, and compatibility with low-dose uniformity requirements.

Poor solubility and dissolution control

Mebendazole has low aqueous solubility. A formulation that dissolves slowly can produce variable in vitro performance and may create additional regulatory scrutiny. Wetting agents, particle-size control, micronization, solid dispersion approaches, and optimized disintegrant systems can improve dissolution.

Sodium lauryl sulfate is one possible wetting agent, but its concentration must be controlled. Excess surfactant can affect taste, gastrointestinal tolerability, tablet hardness, and regulatory acceptability. Alternative surfactants or polymeric solubilization systems may provide a differentiated profile.

Taste and mouthfeel

Mebendazole is associated with an unpleasant taste. This is commercially important because many treatment courses involve children, and some products are intended to be chewed or swallowed without water.

The formulation target is not simply sweetness. A successful pediatric product must control:

• Initial bitterness
• Lingering aftertaste
• Grittiness
• Tablet chalkiness
• Adhesion to the oral cavity
• Flavor intensity after chewing
• Sweetener stability during storage

Taste-masking options include polymer coating, ion-exchange resins, lipid barriers, microencapsulation, flavor layering, and optimized sweetener combinations. A formulation that uses excessive coating can delay disintegration or reduce dose release.

Content uniformity

The 100 mg dose is relatively small compared with the total tablet mass. Poor powder segregation can cause variable active-ingredient distribution. Microcrystalline cellulose, starch, silicon dioxide, and controlled granulation can improve blend uniformity, but the process must be validated for scale-up.

Direct compression may reduce processing steps, while wet granulation may improve uniformity and tablet robustness. The choice depends on particle size, bulk density, flow, moisture sensitivity, and manufacturing economics.

Disintegration and mechanical strength

A chewable tablet must be strong enough for packaging and transport but sufficiently friable during chewing. Excessive lubricant, especially magnesium stearate, can reduce wettability and slow dissolution. Disintegrant concentration and granule porosity require optimization against tablet hardness and friability.

Stability

The excipient system must support stability under temperature and humidity conditions relevant to tropical and subtropical markets. Blister packaging may offer better moisture protection than high-density polyethylene bottles, although bottles can reduce packaging cost and simplify bulk distribution.

What formulations are protected by mebendazole patents?

Mebendazole’s basic active-ingredient protection is mature. Current commercial value is more likely to arise from formulation, manufacturing, delivery, or use claims than from a new composition-of-matter patent.

Formulation patent opportunities

Potentially protectable subject matter includes:

• Taste-masked mebendazole particles
• Rapidly disintegrating chewable tablets
• Pediatric dispersible tablets
• Stable aqueous suspensions
• Improved dissolution compositions
• Amorphous or crystalline solid forms
• Nanoparticle or lipid-based systems
• Fixed-dose combinations with other anthelmintics
• Unit-dose sachets or orally disintegrating formulations
• Manufacturing processes that produce consistent particle size or content uniformity

Patent strength depends on more than the presence of a new excipient. A defensible claim generally requires a defined composition, a credible technical effect, reproducible performance, and data showing a meaningful improvement over conventional mebendazole tablets.

A claim covering a broad list of common excipients may face novelty or obviousness challenges. Narrower claims tied to quantitative ranges, particle-size distributions, dissolution profiles, taste scores, stability results, or manufacturing parameters may be stronger, but they also provide narrower commercial coverage.

How strong is the patent estate for Vermox?

The Vermox franchise does not depend primarily on long-duration compound exclusivity. The commercial protection profile is driven by trademarks, regulatory approvals, manufacturing know-how, distribution, and any jurisdiction-specific formulation or method-of-use rights.

Protection layer	Expected relevance to Vermox
Composition-of-matter patent	Low for the mature mebendazole molecule
Formulation patents	Potentially relevant for new chewables, suspensions, and taste-masking systems
Method-of-use patents	Limited value for established anthelmintic indications; greater potential in new disease areas
Manufacturing know-how	Moderate value, particularly for particle engineering and content uniformity
Trademark	Commercially relevant for brand recognition
Regulatory exclusivity	Product- and jurisdiction-specific
Orange Book protection	Relevant only to approved U.S. products with applicable listed patents
Data exclusivity	Generally less important than formulation and market-access execution

Patent analysis should distinguish the branded Vermox product from U.S. mebendazole products such as Emverm and generic mebendazole approvals. The relevant rights may be owned by different entities and may not cover every country in which Vermox is sold.

What is the Orange Book status of Vermox and mebendazole?

Vermox is not the universal U.S. reference brand for mebendazole. U.S. regulatory analysis must identify the specific approved product, NDA, dosage form, and reference-listed drug in the FDA’s Orange Book and Drugs@FDA databases.[2,3]

For a U.S. generic applicant, the key questions are:

1. Which mebendazole product is the reference listed drug?
2. Are there active patents listed against that product?
3. Are pediatric, formulation, or method-of-use claims listed?
4. Is a Paragraph IV certification required?
5. Does the product qualify for an abbreviated new drug application or require a different regulatory pathway?

An applicant making a Paragraph IV certification could face patent litigation under the Hatch-Waxman framework. A formulation patent may delay approval or launch even where the active ingredient itself is old. The practical litigation risk depends on the scope and remaining term of each listed patent, the applicant’s proposed label, and the patent owner’s enforcement strategy.

When does Vermox lose exclusivity?

Vermox’s basic mebendazole exclusivity is already mature in most markets. The timing of generic entry depends on local registration, trademark rights, supply economics, and any remaining formulation or regulatory protection.

Exclusivity component	General assessment
Active ingredient exclusivity	Generally expired or commercially immaterial
Brand trademark	May remain enforceable indefinitely through continued use and renewal
Formulation exclusivity	Depends on specific patent filings and jurisdictions
Pediatric exclusivity	Product-specific and jurisdiction-specific
Data exclusivity	Depends on the applicable regulatory pathway
Generic entry	Feasible where registration and manufacturing economics support launch

A generic entrant can compete without copying the Vermox brand identity or using every reference-product excipient. The most practical entry product is usually a conventional 100 mg tablet or chewable tablet with a low-cost excipient system and a well-controlled dissolution profile.

What commercial opportunities exist for Vermox excipient suppliers?

Excipient suppliers can target four distinct product strategies.

1. Pediatric taste-masked chewables

This is the most direct opportunity. A supplier can combine sweetener, flavor, coating, and compression technologies into a platform designed for mebendazole and other bitter, low-dose pediatric drugs.

Commercial value comes from reducing development time and improving patient acceptance. The platform should support:

• Low-temperature processing
• Low moisture uptake
• Fast disintegration
• Consistent flavor release
• Compatibility with direct compression
• Regulatory documentation for pediatric use

2. Dispersible and orally disintegrating tablets

Dispersible tablets can improve administration for children who cannot swallow conventional tablets. A low-cost formulation using co-processed excipients, superdisintegrants, and flavor systems could compete in public-health and low-resource settings.

The main technical risks are friability, humidity sensitivity, dose loss during dispersion, and poor taste after the tablet is placed in water.

3. Ready-to-use oral suspensions

An oral suspension can provide dose flexibility and improve administration for young children. The commercial opportunity is strongest where caregivers require weight-based dosing or where tablets are difficult to administer.

The formulation must address mebendazole’s low solubility. A suspension system may use micronized drug, wetting agents, suspending polymers, viscosity modifiers, and preservatives. The product must demonstrate adequate redispersibility, sedimentation control, microbial quality, and dose uniformity throughout the container.

4. Stable, low-cost tropical-market formulations

Many anthelmintic programs operate in regions with high heat, humidity, limited cold-chain infrastructure, and variable distribution conditions. Excipient systems that maintain tablet integrity and dissolution without refrigeration can support institutional procurement.

The strongest value proposition is often a complete formulation package rather than a single excipient. This can include:

• Co-processed diluent-disintegrant
• Low-moisture blister packaging
• Robust tablet coating
• Validated dissolution method
• Stability data under accelerated and long-term conditions
• Scalable manufacturing process

How does Vermox compare with competing anthelmintic products?

Mebendazole competes with albendazole, pyrantel, ivermectin, and other anthelmintic products. Excipient strategy differs by active ingredient, dose, taste profile, and target population.

Product	Main formulation challenge	Excipient opportunity
Mebendazole	Poor solubility and bitterness	Taste-masked chewable, dispersible tablet, suspension
Albendazole	Poor solubility and high-dose administration	Chewable tablet, lipid or wetting system
Pyrantel	Strong taste and liquid-dose use	Flavor, suspension stability, dosing device
Ivermectin	Low dose and sensitive content uniformity	Low-dose blend uniformity, dispersible delivery

Mebendazole’s 100 mg strength is suitable for compact chewable and dispersible products. Albendazole often requires a higher tablet strength, which creates different tablet-size and taste-masking constraints.

Which companies are challenging Vermox or competing in mebendazole?

Competition is fragmented. It includes the Vermox brand owner, generic-drug manufacturers, contract development and manufacturing organizations, excipient suppliers, and public-health suppliers.

The most likely competitive products are:

• Generic 100 mg tablets
• Generic chewable tablets
• Hospital and institutional packs
• Country-specific oral suspensions
• Multi-country branded generics
• Fixed-dose or combination anthelmintic products

The competitive advantage is unlikely to come from the active ingredient alone. It is more likely to come from lower manufacturing cost, reliable supply, pediatric acceptability, regulatory registrations, or access to government procurement channels.

What manufacturing and intellectual-property barriers affect new Vermox formulations?

The principal manufacturing barriers are technical rather than related to active-ingredient scarcity.

Particle engineering

Mebendazole particle size affects blend uniformity, dissolution, segregation, and mouthfeel. Micronization can improve performance but may increase electrostatic behavior, agglomeration, dust control requirements, and manufacturing cost.

Taste-masking scale-up

Taste masking that works in laboratory batches may fail during commercial coating or granulation. Process parameters must control coating thickness, residual solvent or moisture, particle agglomeration, and release after administration.

Excipient regulatory status

A new excipient or an unusual route of administration may require more extensive regulatory justification. Established pharmaceutical excipients with compendial standards and prior oral use generally reduce development friction.

Formulation patents

A developer must screen active patents in each intended market. Relevant claims may cover particle size, excipient ratios, taste-masking layers, dissolution specifications, suspensions, or manufacturing methods. Freedom-to-operate analysis should cover both branded Vermox rights and patents held by other mebendazole developers.

What generic launch scenarios exist for Vermox?

Conventional tablet launch

This is the lowest-cost scenario. The product uses established excipients, standard equipment, and a simple stability program. Price competition is likely to be high.

Chewable-tablet launch

This offers greater differentiation and may support a premium over a conventional tablet. The main development burden is taste, mouthfeel, and pediatric acceptability.

Oral-suspension launch

This offers dose flexibility but has higher packaging, preservative, microbial, and stability requirements. It may be attractive in pediatric and institutional markets.

Platform launch

A company can develop a mebendazole formulation platform that also supports albendazole or other bitter anthelmintics. This approach spreads development cost across multiple products and may create stronger formulation patents.

How should an excipient supplier prioritize commercial development?

The preferred strategy is a low-cost, pediatric-focused system built around established excipients and supported by performance data.

Priority should be given to:

1. A taste-masking system compatible with direct compression.
2. A co-processed diluent-disintegrant with strong flow and low moisture sensitivity.
3. A wetting system that improves dissolution without excessive surfactant use.
4. A suspension platform with validated redispersibility and dose uniformity.
5. Packaging and stability data for hot, humid markets.
6. Formulation support that can be transferred to contract manufacturers.
7. Patent claims based on measurable performance rather than broad ingredient lists.

The commercial package should include formulation prototypes, dissolution data, accelerated stability data, sensory testing, manufacturing instructions, and regulatory documentation. Selling a single excipient is less defensible than selling a validated formulation system.

Key Takeaways

• Vermox contains mebendazole, a mature anthelmintic with limited basic-compound exclusivity.
• Excipient value is concentrated in taste masking, dissolution, content uniformity, disintegration, and tropical stability.
• Pediatric chewables, dispersible tablets, and oral suspensions offer the clearest commercial opportunities.
• Common excipients include lactose, microcrystalline cellulose, starch, povidone, magnesium stearate, talc, silicon dioxide, sweeteners, and wetting agents.
• Formulation patents may remain commercially important even where active-ingredient protection has expired.
• U.S. entry requires product-specific analysis of the reference listed drug, Orange Book listings, and Paragraph IV exposure.
• The strongest supplier proposition is a validated, low-cost excipient platform rather than an isolated ingredient.
• Generic competition is likely to focus on price, supply reliability, pediatric acceptability, and regulatory registrations.

FAQs

Is Vermox the same as mebendazole?

Yes. Vermox is a brand of mebendazole, although approved strengths, dosage forms, indications, and excipients vary by country.

Can lactose-free mebendazole tablets be developed?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, starch, calcium phosphate, or a co-processed excipient system, subject to formulation and regulatory testing.

What is the best dosage form for pediatric mebendazole?

A taste-masked chewable or dispersible tablet is often the most practical balance between patient acceptability, manufacturing cost, and stability. An oral suspension provides greater dose flexibility but has more complex stability and microbiological requirements.

Does improving mebendazole dissolution create patentable subject matter?

It can. Patent strength depends on the specific composition, quantitative ranges, manufacturing process, demonstrated dissolution improvement, and evidence that the result is not predictable from the prior art.

Are excipient suppliers exposed to Vermox patent litigation?

They can be exposed indirectly when supplying a formulation that is alleged to practice a patented composition or manufacturing method. Risk depends on the supplier’s role, contractual indemnities, product specifications, jurisdiction, and the scope of the asserted claims.

References

1. U.S. Food and Drug Administration. (2023). Mebendazole chewable tablets, 100 mg: Prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.
4. World Health Organization. (2023). WHO model list of essential medicines, 23rd list. WHO.
5. European Medicines Agency. (n.d.). Vermox and mebendazole product information. EMA.